Driving role of macrophages in transition from acute kidney injury to chronic kidney disease.
10.1097/CM9.0000000000002100
- Author:
Xiaoming MENG
1
;
Juan JIN
1
;
Hui Yao LAN
2
Author Information
1. Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhul Medical University, The Key Laboratory of Anti-inflammatory of Immune Medicines, Ministry of Education, Hefei, Anhui 230032, China.
2. Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
- Publication Type:Review
- MeSH:
Acute Kidney Injury/drug therapy*;
Disease Progression;
Humans;
Kidney;
Macrophages;
Renal Insufficiency, Chronic
- From:
Chinese Medical Journal
2022;135(7):757-766
- CountryChina
- Language:English
-
Abstract:
Acute kidney injury (AKI), characterized by acute renal dysfunction, is an increasingly common clinical problem and an important risk factor in the subsequent development of chronic kidney disease (CKD). Regardless of the initial insults, the progression of CKD after AKI involves multiple types of cells, including renal resident cells and immune cells such as macrophages. Recently, the involvements of macrophages in AKI-to-CKD transition have garnered significant attention. Furthermore, substantial progress has also been made in elucidating the pathophysiological functions of macrophages from the acute kidney to repair or fibrosis. In this review, we highlight current knowledge regarding the roles and mechanisms of macrophage activation and phenotypic polarization, and transdifferentiation in the development of AKI-to-CKD transition. In addition, the potential of macrophage-based therapy for preventing AKI-to-CKD transition is also discussed.
